Nivolumab for metastatic renal cell carcinoma: Results of a randomized phase II trial

Journal of Clinical Oncology

Volumn 33, Issue 13, 2015, Pages 1430-1437

  Motzer, Robert J ^a   Rini, Brian I ^c   McDermott, David F ^d   Redman, Bruce G ^e   Kuzel, Timothy M ^g   Harrison, Michael R ^h   Vaishampayan, Ulka N ^f   Drabkin, Harry A ⁱ   George, Saby ^b   Logan, Theodore F ^j   Margolin, Kim A ^k   Plimack, Elizabeth R ^l   Lambert, Alexandre M ^m   Waxman, Ian M ^m   Hammers, Hans J ⁿ  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b ROSWELL PARK CANCER INSTITUTE   (United States)

^c TAUSSIG CANCER INSTITUTE   (United States)

^d DANA FARBER HARVARD CANCER CENTER   (United States)

^e UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

^f WAYNE STATE UNIVERSITY   (United States)

^g NORTHWESTERN UNIVERSITY   (United States)

^h DUKE UNIVERSITY MEDICAL CENTER   (United States)

ⁱ MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^j INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^k STANFORD UNIVERSITY   (United States)

^l FOX CHASE CANCER CENTER   (United States)

^m BRISTOL MYERS SQUIBB   (United States)

ⁿ JOHNS HOPKINS UNIVERSITY   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CORTICOSTEROID; CREATININE; EVEROLIMUS; INTERLEUKIN 2; MONOCLONAL ANTIBODY; NIVOLUMAB; PAZOPANIB; SORAFENIB; SUNITINIB; VASCULOTROPIN; VASCULOTROPIN INHIBITOR; ANTINEOPLASTIC AGENT; CD274 PROTEIN, HUMAN; PROGRAMMED DEATH 1 LIGAND 1;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIANGIOGENIC THERAPY; ANTINEOPLASTIC ACTIVITY; ARTHRALGIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CANADA; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER RISK; CANCER SURVIVAL; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CLINICAL EVALUATION; COHORT ANALYSIS; CONTROLLED STUDY; CORTICOSTEROID THERAPY; CREATININE BLOOD LEVEL; DECREASED APPETITE; DIARRHEA; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG RESPONSE; DRUG SAFETY; DRUG SCREENING; DRUG TARGETING; DRY SKIN; FATIGUE; FEMALE; FINLAND; FOLLOW UP; HEART DISEASE; HUMAN; HYPOTHYROIDISM; INCIDENCE; ITALY; KIDNEY METASTASIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTICENTER STUDY; NAUSEA; NEUROLOGIC DISEASE; OBJECTIVE RESPONSE RATE; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIGNAL TRANSDUCTION; SINGLE BLIND PROCEDURE; SKIN PRURITUS; SYSTEMIC THERAPY; THORAX DISEASE; TUMOR IMMUNITY; UNITED STATES; XEROSTOMIA; AGED; ANTAGONISTS AND INHIBITORS; CARCINOMA, RENAL CELL; CLINICAL TRIAL; DISEASE COURSE; DISEASE FREE SURVIVAL; DRUG ADMINISTRATION; IMMUNOLOGY; INTRAVENOUS DRUG ADMINISTRATION; KAPLAN MEIER METHOD; KIDNEY NEOPLASMS; MORTALITY; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; SECONDARY; TIME FACTOR; TREATMENT OUTCOME;

ADMINISTRATION, INTRAVENOUS; AGED; ANTIBODIES, MONOCLONAL; ANTIGENS, CD274; ANTINEOPLASTIC AGENTS; CANADA; CARCINOMA, RENAL CELL; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FINLAND; HUMANS; ITALY; KAPLAN-MEIER ESTIMATE; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES;

EID: 84929572937     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2014.59.0703     Document Type: Article

References (36)

1. Escudier B, Eisen T, Porta C, et al: Renal cell carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 23: vii65-vii71, 2012 (suppl 7)
2. National Comprehensive Cancer Network: NCCN Clinical Practice Guidelines in Oncology: Kidney cancer. http://www.nccn.org/professionals/physician-gls/f-guidelines.asp
3. Finley DS, Pantuck AJ, Belldegrun AS: Tumor biology and prognostic factors in renal cell carcinoma. Oncologist 16:4-13, 2011 (suppl 2)
4. Drake CG, Jaffee E, Pardoll DM: Mechanisms of immune evasion by tumors. Adv Immunol 90:51-81, 2006
5. Mellman I, Coukos G, Dranoff G: Cancer immunotherapy comes of age. Nature 480:480-489, 2011
6. Mizoguchi H, O'Shea JJ, Longo DL, et al: Alterations in signal transduction molecules in T lymphocytes from tumor-bearing mice. Science 258:1795-1798, 1992
7. Topalian SL, Weiner GJ, Pardoll DM: Cancer immunotherapy comes of age. J Clin Oncol 29: 4828-4836, 2011
8. Zitvogel L, Tesniere A, Kroemer G: Cancer despite immunosurveillance: Immunoselection and immunosubversion. Nat Rev Immunol 6:715-727, 2006
9. Bedke J, Gouttefangeas C, Singh-Jasuja H, et al: Targeted therapy in renal cell carcinoma: Moving from molecular agents to specific immunotherapy. World J Urol 32:31-38, 2014
10. Inman BA, Harrison MR, George DJ: Novel immunotherapeutic strategies in development for renal cell carcinoma. Eur Urol 63:881-889, 2013
11. Hamanishi J, Mandai M, Iwasaki M, et al: Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer. Proc Natl Acad Sci U S A 104:3360-3365, 2007
12. Hamid O, Carvajal RD: Anti-programmed death-1 and anti-programmed death-ligand 1 antibodies in cancer therapy. Expert Opin Biol Ther 13:847-861, 2013
13. Nurieva RI, Liu X, Dong C: Molecular mechanisms of T-cell tolerance. Immunol Rev 241:133-144, 2011
14. Brahmer JR, Drake CG, Wollner I, et al: Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: Safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol 28:3167-3175, 2010
15. Topalian SL, Hodi FS, Brahmer JR, et al: Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366:2443-2454, 2012
16. Motzer RJ, Bacik J, Schwartz LH, et al: Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. J Clin Oncol 22:454-463, 2004
17. International Conference on Harmonisation Expert Working Group: Guidance for Industry: E6 Good Clinical Practice - Consolidated Guidance. http://www.fda.gov/downloads/Drugs/Guidances/ucm073122.pdf
18. World Medical Association: World Medical Association Declaration of Helsinki: Ethical Principles for Medical Research Involving Human Subjects. http://www.wma.net/en/30publications/10policies/b3/17c.pdf
19. Wolchok JD, Hoos A, O'Day S, et al: Guidelines for the evaluation of immune therapy activity in solid tumors: Immune-related response criteria. Clin Cancer Res 15:7412-7420, 2009
20. National Cancer Institute: Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. http://ctep.cancer.gov/protocolDevelopment/electronic-applications/ctc.htm#ctc-40
21. Cogswell JP, Goldberg SM, Gupta AK, et al: Cancer immunotherapy by disrupting pd-1/pd-l1 signaling. http://www.freepatentsonline.com/20130309250.pdf
22. Dong H, Strome SE, Salomao DR, et al: Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion. Nat Med 8:793-800, 2002
23. Taube JM, Anders RA, Young GD, et al: Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med 4:127ra37, 2012
24. Cox DR: Regression models and life tables. J R Stat Soc B 34:187-220, 1972
25. Clopper CJ, Pearson ES: The use of confidence or fiducial limits illustrated in the case of the binomial. Biometrika 26:404-413, 1934
26. Armitage P: Tests for linear trends in proportions and frequencies. Biometrics (International Biometric Society) 11:375-386, 1955
27. Cochran WG: Some methods for strengthening the common chi-squared tests. Biometrics (International Biometric Society) 10:417-451, 1954
28. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
29. Hutson TE, Escudier B, Esteban E, et al: Randomized phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma. J Clin Oncol 32:760-767, 2014
30. Motzer RJ, Escudier B, Oudard S, et al: Phase 3 trial of everolimus for metastatic renal cell carcinoma: Final results and analysis of prognostic factors. Cancer 116:4256-4265, 2010
31. Motzer RJ, Escudier B, Tomczak P, et al: Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: Overall survival analysis and updated results from a randomised phase 3 trial. Lancet Oncol 14:552-562, 2013
32. Motzer RJ, Porta C, Vogelzang NJ, et al: Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: An open-label, randomised phase 3 trial. Lancet Oncol 15:286-296, 2014
33. Wolchok JD, Kluger H, Callahan MK, et al: Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 369:122-133, 2013
34. Choueiri TK, Fishman MN, Escudier BJ, et al: Immunomodulatory activity of nivolumab in previously treated and untreated metastatic renal cell carcinoma (mRCC): Biomarker-based results from a randomized clinical trial. J Clin Oncol 32, 2014 (suppl 15s; abstr 5012)
35. McDermott DF, Drake CG, Sznol M, et al: Clinical activity and safety of antiprogrammed death-1 (PD-1) (BMS-936558/MDX-1106/ONO-4538) in patients (pts) with previously treated, metastatic renal cell carcinoma (mRCC): An updated analysis. J Clin Oncol 31, 2013 (suppl; abstr 351)
36. Hammers HJ, Plimack ER, Infante JR, et al: Phase I study of nivolumab in combination with ipilimumab in metastatic renal cell carcinoma (mRCC). J Clin Oncol 32:297s, 2014 (suppl 15s; abstr 4504)